NasdaqGS:CABABiotechs
Assessing Cabaletta Bio (CABA) Valuation After 10 Year Cellares Supply Deal And Upcoming Rese Cel Data
Cabaletta Bio (CABA) has drawn fresh attention after entering a 10-year commercial supply agreement with Cellares for automated rese cel manufacturing, alongside upcoming clinical and translational presentations at a major gene and cell therapy meeting.
See our latest analysis for Cabaletta Bio.
The recent 10 year manufacturing agreement with Cellares and upcoming rese cel data presentations come on the back of strong momentum, with a 1 day share price return of 30.27% and a year to date...